hERG MAP-A rational approach to eliminate ion channel related cardiotoxicity
hERG MAP-A rational approach to eliminate ion channel related cardiotoxicity
批准号:
7053087
负责人:
Mark W Nowak
金额:
$21.71万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-09-28 至 2007-03-27
关键词:
CHO cellsacylationaminoacidaminoacyl tRNAarrhythmiabioassaycardiotoxincell linecomputer simulationdrug discovery /isolationelectrophysiologyhydropathyinjection /infusionintermolecular interactionion channel blockerion transportmutantpharmacokineticspotassium channeltissue /cell culturetransfection /expression vectorvoltage /patch clamp
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): hERG K+ channel inhibition by drugs is implicated in cardiac arrhythmias and sudden death. Several drugs were removed from the market due to hERG-related cardiotoxicity New methods are needed for eliminating hERG binding to new drugs. Drug development will benefit substantially from new experimentally-derived insights into the structural basis for hERG block. Neurion has developed a unique approach, the hERG MAP(tm) that identifies the key interactions drugs make with the hERG channel. The data guide medicinal chemists in synthetically reducing or eliminating hERG binding. We validated our rational approach in successful collaborations with major pharmaceutical companies. Currently we express hERG channels in Xenopus oocytes. The yolk of the oocyte is large and hydrophobic, and appears to adsorb drugs. Importantly, yolk binding makes drug affinities estimates measured in oocytes appear less than those measured in mammalian cells. This limits our ability to directly estimate affinity and to measure weakly binding drugs. In order make our current approach more widely applicable and in line with current pharmaceutical company practice, we propose to adopt hERG MAP for mammalian cell expression systems. In Aim 1 we will elucidate the binding interactions and channel block of six drugs with WT hERG and hERG mutated at critical binding residues expressed in mammalian cells; in Aim 2 we will apply the in vivo nonsense suppression methodology to generate unnatural hERG mutants using laser based (optical) injection to deliver exogenous amino acylated tRNA into mammalian cells. The result of the Phase I work will be wildly applicable, mammalian cell-based hERG assays that can directly aid medicinal chemists in eliminating hERG toxicity. In Phase II we will industrialize the assay by establishing the expression of all relevant hERG mutants in mammalian cells and optimizing the technology for higher- throughput, automated electrophysiology measurements. We will also assay a substantial number of molecules and conduct the computational interpretation needed to create a large database of drug-hERG interactions. Finally, we will also demonstrate the synthetic "rescue" of a known hERG-blocking molecule.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Real Time NEURON Simulation for Experimental Applications
-
批准号:10384810
-
项目类别:
-
资助金额:$25.66万
-
财政年份:2022
-
负责人:Mark W Nowak
-
依托单位:
Advanced Dynamic Clamp for Neuroscience
-
批准号:10868186
-
项目类别:
-
资助金额:$37.86万
-
财政年份:2018
-
负责人:Mark W Nowak
-
依托单位:
Advanced Dynamic Clamp for Neuroscience
-
批准号:10483575
-
项目类别:
-
资助金额:$86.08万
-
财政年份:2018
-
负责人:Mark W Nowak
-
依托单位:
Advanced Dynamic Clamp for Neuroscience
-
批准号:10577885
-
项目类别:
-
资助金额:$85.89万
-
财政年份:2018
-
负责人:Mark W Nowak
-
依托单位:
Advanced Dynamic Clamp for Neuroscience
-
批准号:10213208
-
项目类别:
-
资助金额:$5.5万
-
财政年份:2018
-
负责人:Mark W Nowak
-
依托单位:
Oral delivery of peptides targeting intracellular protein-protein interactions
-
批准号:8251999
-
项目类别:
-
资助金额:$22.92万
-
财政年份:2012
-
负责人:Mark W Nowak
-
依托单位:
Using a cyclotide-based molecular scaffold to select specific protein-protein inh
-
批准号:7996667
-
项目类别:
-
资助金额:$20.07万
-
财政年份:2010
-
负责人:Mark W Nowak
-
依托单位:
Novel assay to identify anti-thrombotic agents
-
批准号:7669701
-
项目类别:
-
资助金额:$20.52万
-
财政年份:2009
-
负责人:Mark W Nowak
-
依托单位:
Novel drug discovery assay to identify inhibitors of NFkB signaling
-
批准号:7669696
-
项目类别:
-
资助金额:$20.52万
-
财政年份:2009
-
负责人:Mark W Nowak
-
依托单位:
High Throughput Screening Technology for Allosteric Kinase Inhibitors
-
批准号:7608761
-
项目类别:
-
资助金额:$20.45万
-
财政年份:2008
-
负责人:Mark W Nowak
-
依托单位:
Novel assay to identify non-ATP competitive protein kinase inhibitors
-
批准号:7271467
-
项目类别:
-
资助金额:$20.13万
-
财政年份:2007
-
负责人:Mark W Nowak
-
依托单位:
Cell-Based Technology for Protein-Protein Interactions
-
批准号:7154293
-
项目类别:
-
资助金额:$13.48万
-
财政年份:2006
-
负责人:Mark W Nowak
-
依托单位:
COMPOUNDS TARGETING THE ALPHA-2 GABA-A RECEPTOR SUBTYPE
-
批准号:7215500
-
项目类别:
-
资助金额:$6.0万
-
财政年份:2005
-
负责人:Mark W Nowak
-
依托单位:
COMPOUNDS TARGETING THE ALPHA-2 GABA-A RECEPTOR SUBTYPE
-
批准号:7068129
-
项目类别:
-
资助金额:$25.0万
-
财政年份:2005
-
负责人:Mark W Nowak
-
依托单位:
COMPOUNDS TARGETING THE ALPHA-2 GABA-A RECEPTOR SUBTYPE
-
批准号:6937502
-
项目类别:
-
资助金额:$25.0万
-
财政年份:2005
-
负责人:Mark W Nowak
-
依托单位:
ETHANOL EFFECTS ON NICOTINIC ACETYLCHOLINE RECEPTORS
-
批准号:6532341
-
项目类别:
-
资助金额:$11.7万
-
财政年份:1999
-
负责人:Mark W Nowak
-
依托单位:
ETHANOL EFFECTS ON NICOTINIC ACETYLCHOLINE RECEPTORS
-
批准号:2884769
-
项目类别:
-
资助金额:$11.12万
-
财政年份:1999
-
负责人:Mark W Nowak
-
依托单位:
ETHANOL EFFECTS ON NICOTINIC ACETYLCHOLINE RECEPTORS
-
批准号:6168166
-
项目类别:
-
资助金额:$11.03万
-
财政年份:1999
-
负责人:Mark W Nowak
-
依托单位:
ETHANOL EFFECTS ON NICOTINIC ACETYLCHOLINE RECEPTORS
-
批准号:6371241
-
项目类别:
-
资助金额:$11.3万
-
财政年份:1999
-
负责人:Mark W Nowak
-
依托单位:
STRUCTURE/FUNCTION OF NICOTINIC RECEPTOR CHANNELS
-
批准号:2169765
-
项目类别:
-
资助金额:$2.99万
-
财政年份:1994
-
负责人:Mark W Nowak
-
依托单位:
国内基金
海外基金
TLS聚合酶Polη乙酰化修饰的动态调控和功能研究
-
批准号:31970740
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2019
-
负责人:郭彩霞
-
依托单位: